Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer von Hadoux, Julien, Elisei, Rossella, Brose, Marcia S., Hoff, Ana O., Robinson, Bruce G., Gao, Ming, Jarzab, Barbara, Isaev, Pavel, Kopeckova, Katerina, Wadsley, Jonathan, Führer, Dagmar, Keam, Bhumsuk, Bardet, Stéphane, Sherman, Eric J., Tahara, Makoto, Hu, Mimi I., Singh, Ravinder, Lin, Yan, Soldatenkova, Victoria, Wright, Jennifer, Lin, Boris, Maeda, Patricia, Capdevila, Jaume, Wirth, Lori J.

Volltext

Update on Anti-EGFR Targeted Therapy von Thongprasert, Sumitra, Ma, Brigette B., Fasching, Peter A., Chua, Daniel, Wirth, Lori

Volltext

Jeopardy: Using a Familiar Game to Teach Health von Wirth, Lori A., Breiner, Judy

Volltext

Vemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, ph... von Brose, Marcia S, Dr, Cabanillas, Maria E, MD, Cohen, Ezra E W, Prof, Wirth, Lori J, MD, Riehl, Todd, PharmD, Yue, Huibin, PhD, Sherman, Steven I, Prof, Sherman, Eric J, MD

Volltext

An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma von Pappa, Theodora, Wirth, Lori

Volltext

PD-1 Blockade in Anaplastic Thyroid Carcinoma von Capdevila, Jaume, Wirth, Lori J, Ernst, Thomas, Ponce Aix, Santiago, Lin, Chia-Chi, Ramlau, Rodryg, Butler, Marcus O, Delord, Jean-Pierre, Gelderblom, Hans, Ascierto, Paolo A, Fasolo, Angelica, Führer, Dagmar, Hütter-Krönke, Marie Luise, Forde, Patrick M, Wrona, Anna, Santoro, Armando, Sadow, Peter M, Szpakowski, Sebastian, Wu, Hongqian, Bostel, Geraldine, Faris, Jason, Cameron, Scott, Varga, Andreea, Taylor, Matthew

Volltext

Management of patients with NTRK fusion-positive thyroid cancer von Wirth, Lori J

Volltext

Still Perfecting Radioiodine in Thyroid Cancer, After All These Years von Wirth, Lori J

Volltext

Cabozantinib in Progressive Medullary Thyroid Cancer von Elisei, Rossella, Schlumberger, Martin J, Müller, Stefan P, Schöffski, Patrick, Brose, Marcia S, Shah, Manisha H, Licitra, Lisa, Jarzab, Barbara, Medvedev, Viktor, Kreissl, Michael C, Niederle, Bruno, Cohen, Ezra E W, Wirth, Lori J, Ali, Haythem, Hessel, Colin, Yaron, Yifah, Ball, Douglas, Nelkin, Barry, Sherman, Steven I

Volltext

SY33-2 New perspectives on the treatment of thyroid cancer: novel drugs for medullary thyroid cancer von Wirth, Lori J.

Volltext

Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment von Nakaguro, Masato, Tada, Yuichiro, Faquin, William C., Sadow, Peter M., Wirth, Lori J., Nagao, Toshitaka

Volltext

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, p... von Brose, Marcia S, Cabanillas, Maria E, Cohen, Ezra E W, Wirth, Lori J, Riehl, Todd, Yue, Huibin, Sherman, Steven I, Sherman, Eric J

Volltext

Treatment‐emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT) von Wirth, Lori J., Tahara, Makoto, Robinson, Bruce, Francis, Sanjeev, Brose, Marcia S., Habra, Mouhammed Amir, Newbold, Kate, Kiyota, Naomi, Dutcus, Corina E., Mathias, Elton, Guo, Matthew, Sherman, Steven I., Schlumberger, Martin

Volltext

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib von Rothenberg, S Michael, McFadden, David G, Palmer, Edwin L, Daniels, Gilbert H, Wirth, Lori J

Volltext

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer von Tahara, Makoto, Brose, Marcia S., Wirth, Lori J., Suzuki, Takuya, Miyagishi, Hideaki, Fujino, Katsuki, Dutcus, Corina E., Gianoukakis, Andrew

Volltext

Accelerated approvals hit the target in precision oncology von Subbiah, Vivek, Wirth, Lori J., Kurzrock, Razelle, Pazdur, Richard, Beaver, Julia A., Singh, Harpreet, Mehta, Gautam U.

Volltext

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study von Bauml, Joshua, Seiwert, Tanguy Y, Pfister, David G, Worden, Francis, Liu, Stephen V, Gilbert, Jill, Saba, Nabil F, Weiss, Jared, Wirth, Lori, Sukari, Ammar, Kang, Hyunseok, Gibson, Michael K, Massarelli, Erminia, Powell, Steven, Meister, Amy, Shu, Xinxin, Cheng, Jonathan D, Haddad, Robert

Volltext

Medullary Thyroid Cancer: Updates and Challenges von Gild, Matti L, Clifton-Bligh, Roderick J, Wirth, Lori J, Robinson, Bruce G

Volltext

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer von Robinson, Bruce, Schlumberger, Martin, Wirth, Lori J, Dutcus, Corina E, Song, James, Taylor, Matthew H, Kim, Sung-Bae, Krzyzanowska, Monika K, Capdevila, Jaume, Sherman, Steven I, Tahara, Makoto

Volltext

Amygdalar activity measured using FDG-PET/CT at head and neck cancer staging independently predicts survival von Hassan, Malek Z O, Tawakol, Ahmed, Wang, Ying, Alvi, Raza M, Awadalla, Magid, Jones-O'Connor, Maeve, B Bakar, Rula, Banerji, Dahlia, Rokicki, Adam, Zhang, Lili, Mulligan, Connor P, Osborne, Michael T, Zarif, Azmaeen, Hammad, Basma, Chan, Annie W, Wirth, Lori J, Warner, Erica T, Pitman, Roger K, Armstrong, Katrina A, Addison, Daniel, Neilan, Tomas G

Volltext